In addition, the FDA approved anti-PD-1 for the treatment of Hodgkin lymphoma, non-small-cell lung carcinoma (NSCLC), RCC, and head and neck squamous cell carcinoma (HNSCC), because clinical trials demonstrated the safety and efficacy in these cancer types (21–26). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.